$30,000 of MIMEDX lobbying was just disclosed, from Q3 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"regulatory issues related to the delivery of wound management and skin substitutes for Medicare patients"
You can find more data on corporate lobbying on Quiver Quantitative.
MDXG Hedge Fund Activity
We have seen 100 institutional investors add shares of MDXG stock to their portfolio, and 94 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FIRST LIGHT ASSET MANAGEMENT, LLC removed 1,525,580 shares (-44.2%) from their portfolio in Q2 2025, for an estimated $9,321,293
- BLACKROCK, INC. added 1,346,741 shares (+13.2%) to their portfolio in Q2 2025, for an estimated $8,228,587
- HARBOR CAPITAL ADVISORS, INC. removed 833,432 shares (-71.3%) from their portfolio in Q3 2025, for an estimated $5,817,355
- TRIGRAN INVESTMENTS, INC. added 790,901 shares (+10.4%) to their portfolio in Q2 2025, for an estimated $4,832,405
- ROYCE & ASSOCIATES LP removed 577,703 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $3,529,765
- AMERIPRISE FINANCIAL INC added 548,767 shares (+5332.5%) to their portfolio in Q2 2025, for an estimated $3,352,966
- MILLENNIUM MANAGEMENT LLC added 442,379 shares (+35.9%) to their portfolio in Q2 2025, for an estimated $2,702,935
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
MDXG Analyst Ratings
Wall Street analysts have issued reports on $MDXG in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Cantor Fitzgerald issued a "Overweight" rating on 07/31/2025
To track analyst ratings and price targets for MDXG, check out Quiver Quantitative's $MDXG forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
